US-based precision medicine developer Syapse received $30m on Tuesday in a series D round backed by a range of corporate investors including clinical trial software provider Medidata Solutions.
Pharmaceutical firms Amgen, Merck & Co and Roche took part through respective subsidiaries Amgen Ventures, Merck Global Health Innovation Fund and Roche Venture Fund.
Ascension Ventures and Intermountain Healthcare Innovation Fund, vehicles for care providers Ascension and Intermountain, also contributed, as did industrial product maker General Electric’s GE Ventures unit, Safeguard Scientifics and Social Capital.
Syapse has created a personalised cancer treatment system that incorporates a dedicated software platform and a network where its industry partners can share data with each other through a single ecosystem.
The round brought Syapse’s overall funding to $69.5m, and follows a $25m series C led by Ascension Ventures in January 2016 that included capital from existing investors Social Capital and Safeguard Scientifics.
Ascension Ventures investment director John Kuelper said: “Targeted therapeutics and precision diagnostics have been shown to save lives and lower the cost of care, but without tools like Syapse, they have been inaccessible to the community oncologists that represent 70% of patient care.
“Syapse empowers physicians to collaborate with each other and the broader medical ecosystem, ensuring that these breakthrough technologies are available to the patients who need them.”